PEG-3350 and Electrolytes
NDC 50090-6521, Polyethylene Glycol 3350, Sodium Sulfate Anhydrous, Sodium Bicarbonate, Sodium Chloride, Potassium Chloride, powder, for solution, from A-S Medication Solutions.
- Product NDC
- 50090-6521
- Status
- Listed
- Labeler
- A-S Medication Solutions
- Dosage form
- POWDER, FOR SOLUTION
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA AUTHORIZED GENERIC
- Application
- NDA019011
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/50090-6521 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- POLYETHYLENE GLYCOL 3350236 g/4L
- SODIUM SULFATE ANHYDROUS22.74 g/4L
- SODIUM BICARBONATE6.74 g/4L
- SODIUM CHLORIDE5.86 g/4L
- POTASSIUM CHLORIDE2.97 g/4L
Pharmacologic classes
Increased Large Intestinal Motility [PE]; Increased Large Intestinal Motility [PE]; Increased Large Intestinal Motility [PE]; Increased Large Intestinal Motility [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]; Osmotic Activity [MoA]; Osmotic Activity [MoA]; Osmotic Activity [MoA]; Osmotic Activity [MoA]; Osmotic Activity [MoA]; Osmotic Laxative [EPC]; Osmotic Laxative [EPC]; Osmotic Laxative [EPC]; Osmotic Laxative [EPC]; Osmotic Laxative [EPC]; Potassium Compounds [CS]; Potassium Salt [EPC]; Stimulation Large Intestine Fluid/Electrolyte Secretion [PE]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 50090-6521-0 | 50090652100 | 4 L in 1 JUG (50090-6521-0) |
Linked data
RxNorm, label and prices
Related lookups
FDA label sections
GET /v1/drugs/labels/7a2d8dab-750f-43c1-933c-4169a840c60c
Use it
Look up 50090-6521 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/50090-6521 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 50090-6521. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.